Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Stroke | 100 | 2022 | 2160 | 6.310 |
Why?
|
Brain Ischemia | 48 | 2020 | 665 | 5.150 |
Why?
|
Emergency Medical Services | 25 | 2022 | 224 | 3.600 |
Why?
|
Tissue Plasminogen Activator | 35 | 2018 | 296 | 2.910 |
Why?
|
Fibrinolytic Agents | 29 | 2018 | 377 | 2.500 |
Why?
|
Thrombolytic Therapy | 17 | 2017 | 233 | 1.670 |
Why?
|
Cerebral Hemorrhage | 15 | 2019 | 198 | 1.540 |
Why?
|
Endovascular Procedures | 16 | 2018 | 366 | 1.530 |
Why?
|
Thrombectomy | 10 | 2020 | 238 | 1.380 |
Why?
|
American Heart Association | 15 | 2021 | 142 | 1.370 |
Why?
|
Cardiopulmonary Resuscitation | 5 | 2018 | 72 | 1.250 |
Why?
|
Emergency Service, Hospital | 9 | 2020 | 711 | 0.950 |
Why?
|
Humans | 143 | 2022 | 68504 | 0.940 |
Why?
|
Emergency Treatment | 3 | 2015 | 52 | 0.920 |
Why?
|
Manikins | 1 | 2022 | 42 | 0.880 |
Why?
|
Acute Coronary Syndrome | 3 | 2021 | 195 | 0.880 |
Why?
|
Cerebral Angiography | 7 | 2019 | 151 | 0.780 |
Why?
|
Computed Tomography Angiography | 2 | 2021 | 424 | 0.750 |
Why?
|
Practice Guidelines as Topic | 10 | 2021 | 772 | 0.750 |
Why?
|
Certification | 3 | 2020 | 66 | 0.740 |
Why?
|
Urban Population | 2 | 2021 | 254 | 0.740 |
Why?
|
Brain Edema | 1 | 2019 | 50 | 0.720 |
Why?
|
Organizational Policy | 1 | 2019 | 42 | 0.700 |
Why?
|
Early Diagnosis | 1 | 2019 | 122 | 0.700 |
Why?
|
Infarction, Middle Cerebral Artery | 2 | 2019 | 105 | 0.700 |
Why?
|
Intracranial Hypertension | 1 | 2019 | 53 | 0.690 |
Why?
|
Aged | 53 | 2019 | 14841 | 0.690 |
Why?
|
Defibrillators | 1 | 2018 | 11 | 0.670 |
Why?
|
United States | 35 | 2021 | 7333 | 0.670 |
Why?
|
Disease Management | 5 | 2021 | 248 | 0.660 |
Why?
|
Rural Population | 2 | 2021 | 397 | 0.660 |
Why?
|
Intracranial Hemorrhages | 2 | 2015 | 80 | 0.650 |
Why?
|
Physicians | 3 | 2018 | 324 | 0.640 |
Why?
|
Neurology | 2 | 2015 | 43 | 0.610 |
Why?
|
Middle Aged | 54 | 2019 | 21115 | 0.600 |
Why?
|
Patient Selection | 6 | 2012 | 592 | 0.600 |
Why?
|
Cerebral Revascularization | 2 | 2014 | 45 | 0.570 |
Why?
|
Life Support Care | 1 | 2015 | 12 | 0.570 |
Why?
|
Tomography, X-Ray Computed | 13 | 2021 | 2323 | 0.560 |
Why?
|
Time Factors | 26 | 2018 | 4655 | 0.550 |
Why?
|
Female | 69 | 2020 | 38003 | 0.550 |
Why?
|
Male | 69 | 2020 | 37265 | 0.550 |
Why?
|
Acute Disease | 14 | 2019 | 658 | 0.530 |
Why?
|
Data Interpretation, Statistical | 6 | 2014 | 329 | 0.520 |
Why?
|
Health Knowledge, Attitudes, Practice | 4 | 2021 | 766 | 0.520 |
Why?
|
Guideline Adherence | 3 | 2017 | 284 | 0.510 |
Why?
|
Hospitals | 3 | 2022 | 265 | 0.500 |
Why?
|
Time-to-Treatment | 5 | 2022 | 117 | 0.500 |
Why?
|
Ischemic Attack, Transient | 5 | 2008 | 167 | 0.500 |
Why?
|
Magnetic Resonance Angiography | 2 | 2012 | 181 | 0.480 |
Why?
|
Treatment Outcome | 28 | 2020 | 7026 | 0.470 |
Why?
|
Primary Health Care | 2 | 2021 | 702 | 0.460 |
Why?
|
Cardiology | 2 | 2010 | 140 | 0.440 |
Why?
|
Surgery, Computer-Assisted | 1 | 2012 | 52 | 0.440 |
Why?
|
Blood Pressure | 4 | 2015 | 1447 | 0.430 |
Why?
|
Societies, Medical | 4 | 2019 | 403 | 0.390 |
Why?
|
Feasibility Studies | 3 | 2022 | 652 | 0.380 |
Why?
|
Delivery of Health Care | 4 | 2021 | 445 | 0.380 |
Why?
|
S100 Proteins | 2 | 2008 | 42 | 0.380 |
Why?
|
Nerve Growth Factors | 2 | 2008 | 75 | 0.370 |
Why?
|
Severity of Illness Index | 10 | 2018 | 1851 | 0.360 |
Why?
|
Quality Improvement | 2 | 2017 | 413 | 0.360 |
Why?
|
Reperfusion | 3 | 2014 | 78 | 0.340 |
Why?
|
Hematoma | 2 | 2006 | 47 | 0.330 |
Why?
|
Adult | 33 | 2021 | 21373 | 0.330 |
Why?
|
Recombinant Proteins | 7 | 2019 | 742 | 0.330 |
Why?
|
South Carolina | 6 | 2022 | 2750 | 0.330 |
Why?
|
Recovery of Function | 5 | 2017 | 506 | 0.310 |
Why?
|
Electrocardiography | 2 | 2008 | 601 | 0.310 |
Why?
|
Subarachnoid Hemorrhage | 4 | 2019 | 61 | 0.300 |
Why?
|
Thrombomodulin | 1 | 2006 | 3 | 0.300 |
Why?
|
Ischemia | 2 | 2018 | 229 | 0.300 |
Why?
|
Myelin Basic Protein | 1 | 2006 | 62 | 0.290 |
Why?
|
Phosphopyruvate Hydratase | 1 | 2006 | 35 | 0.290 |
Why?
|
Emergency Medicine | 2 | 2005 | 88 | 0.290 |
Why?
|
Retrospective Studies | 14 | 2018 | 7263 | 0.290 |
Why?
|
Hypertension | 9 | 2014 | 1531 | 0.280 |
Why?
|
Hospitalization | 6 | 2019 | 976 | 0.280 |
Why?
|
Gene Expression Profiling | 8 | 2014 | 498 | 0.280 |
Why?
|
Aged, 80 and over | 23 | 2019 | 4843 | 0.270 |
Why?
|
Triage | 3 | 2020 | 109 | 0.270 |
Why?
|
Myocardial Ischemia | 1 | 2006 | 172 | 0.270 |
Why?
|
Critical Care | 3 | 2022 | 263 | 0.270 |
Why?
|
Risk Factors | 22 | 2019 | 5719 | 0.260 |
Why?
|
Consensus | 2 | 2021 | 211 | 0.260 |
Why?
|
Neuroprotective Agents | 2 | 2004 | 317 | 0.250 |
Why?
|
Biomedical Research | 5 | 2019 | 310 | 0.250 |
Why?
|
Logistic Models | 9 | 2013 | 1419 | 0.250 |
Why?
|
Cerebrovascular Disorders | 4 | 2005 | 182 | 0.250 |
Why?
|
Free Radical Scavengers | 1 | 2004 | 112 | 0.240 |
Why?
|
Central Nervous System | 1 | 2004 | 107 | 0.240 |
Why?
|
Hemodynamics | 1 | 2006 | 705 | 0.230 |
Why?
|
Clinical Trials as Topic | 3 | 2014 | 848 | 0.230 |
Why?
|
Advisory Committees | 3 | 2014 | 73 | 0.230 |
Why?
|
Randomized Controlled Trials as Topic | 7 | 2015 | 929 | 0.230 |
Why?
|
Airway Management | 1 | 2022 | 20 | 0.220 |
Why?
|
Sex Characteristics | 3 | 2014 | 295 | 0.220 |
Why?
|
Perfusion | 2 | 2012 | 131 | 0.220 |
Why?
|
Patient Acceptance of Health Care | 3 | 2019 | 467 | 0.220 |
Why?
|
Glasgow Coma Scale | 4 | 2019 | 65 | 0.220 |
Why?
|
Adolescent | 16 | 2018 | 8903 | 0.210 |
Why?
|
Primary Prevention | 2 | 2014 | 115 | 0.210 |
Why?
|
ST Elevation Myocardial Infarction | 1 | 2021 | 10 | 0.210 |
Why?
|
Biomarkers | 9 | 2014 | 1593 | 0.210 |
Why?
|
Ambulances | 2 | 2019 | 26 | 0.200 |
Why?
|
Prospective Studies | 11 | 2017 | 3702 | 0.200 |
Why?
|
Health Care Surveys | 3 | 2018 | 239 | 0.200 |
Why?
|
Emergency Medical Technicians | 3 | 2007 | 14 | 0.200 |
Why?
|
Gene Expression Regulation | 3 | 2014 | 1290 | 0.200 |
Why?
|
Atrial Fibrillation | 3 | 2015 | 248 | 0.200 |
Why?
|
Infusions, Intravenous | 8 | 2017 | 334 | 0.200 |
Why?
|
Survival Analysis | 2 | 2018 | 714 | 0.190 |
Why?
|
Emergency Medical Service Communication Systems | 2 | 2012 | 25 | 0.190 |
Why?
|
Telemedicine | 4 | 2016 | 698 | 0.190 |
Why?
|
Factor VIIa | 1 | 2019 | 25 | 0.190 |
Why?
|
Early Medical Intervention | 2 | 2016 | 16 | 0.180 |
Why?
|
Patient Transfer | 3 | 2021 | 86 | 0.180 |
Why?
|
Common Data Elements | 1 | 2019 | 4 | 0.180 |
Why?
|
Young Adult | 9 | 2018 | 5708 | 0.180 |
Why?
|
Antihypertensive Agents | 3 | 2014 | 497 | 0.180 |
Why?
|
Aneurysm, Ruptured | 1 | 2019 | 40 | 0.180 |
Why?
|
Gene Expression | 2 | 2012 | 769 | 0.180 |
Why?
|
Quality of Health Care | 3 | 2011 | 322 | 0.170 |
Why?
|
Double-Blind Method | 5 | 2019 | 1734 | 0.170 |
Why?
|
Aspirin | 2 | 2018 | 295 | 0.170 |
Why?
|
Brain | 4 | 2019 | 2175 | 0.170 |
Why?
|
Research | 2 | 2017 | 214 | 0.170 |
Why?
|
Risk Assessment | 4 | 2021 | 2004 | 0.170 |
Why?
|
Transportation of Patients | 3 | 2012 | 46 | 0.170 |
Why?
|
Out-of-Hospital Cardiac Arrest | 1 | 2018 | 11 | 0.170 |
Why?
|
Headache | 1 | 1998 | 68 | 0.170 |
Why?
|
Emergency Nursing | 2 | 2007 | 9 | 0.160 |
Why?
|
First Aid | 2 | 2007 | 8 | 0.160 |
Why?
|
Heart Arrest | 2 | 2008 | 113 | 0.160 |
Why?
|
Brain Injuries | 3 | 2014 | 268 | 0.160 |
Why?
|
Health Personnel | 2 | 2011 | 286 | 0.160 |
Why?
|
Awareness | 1 | 1998 | 81 | 0.160 |
Why?
|
Health Services Accessibility | 2 | 2016 | 581 | 0.160 |
Why?
|
Cost-Benefit Analysis | 3 | 2017 | 503 | 0.160 |
Why?
|
Odds Ratio | 9 | 2019 | 880 | 0.160 |
Why?
|
Risk Adjustment | 1 | 2017 | 49 | 0.160 |
Why?
|
Medically Uninsured | 1 | 2018 | 99 | 0.150 |
Why?
|
Research Design | 4 | 2014 | 729 | 0.150 |
Why?
|
Focal Infection, Dental | 1 | 1996 | 1 | 0.150 |
Why?
|
Facial Muscles | 1 | 1996 | 11 | 0.150 |
Why?
|
Neck Muscles | 1 | 1996 | 6 | 0.150 |
Why?
|
Health Care Costs | 2 | 2017 | 346 | 0.150 |
Why?
|
Apolipoproteins E | 4 | 2005 | 92 | 0.150 |
Why?
|
Fasciitis, Necrotizing | 1 | 1996 | 15 | 0.150 |
Why?
|
National Institutes of Health (U.S.) | 3 | 2018 | 109 | 0.150 |
Why?
|
Poverty | 1 | 2018 | 218 | 0.150 |
Why?
|
Ohio | 8 | 2009 | 64 | 0.140 |
Why?
|
Population Surveillance | 1 | 1998 | 285 | 0.140 |
Why?
|
National Institute of Neurological Disorders and Stroke (U.S.) | 2 | 2019 | 20 | 0.140 |
Why?
|
Disability Evaluation | 5 | 2020 | 298 | 0.140 |
Why?
|
Meta-Analysis as Topic | 1 | 2015 | 57 | 0.140 |
Why?
|
Oxidative Stress | 2 | 2014 | 718 | 0.140 |
Why?
|
Health Education | 4 | 2021 | 279 | 0.140 |
Why?
|
Algorithms | 4 | 2013 | 1194 | 0.140 |
Why?
|
Surveys and Questionnaires | 3 | 2019 | 2798 | 0.140 |
Why?
|
Models, Theoretical | 1 | 2018 | 384 | 0.130 |
Why?
|
Hospital Units | 2 | 2012 | 21 | 0.130 |
Why?
|
Community-Based Participatory Research | 1 | 2016 | 133 | 0.130 |
Why?
|
Statistics as Topic | 1 | 2015 | 219 | 0.130 |
Why?
|
Nervous System Diseases | 2 | 2018 | 142 | 0.130 |
Why?
|
Intracranial Embolism | 1 | 2014 | 25 | 0.130 |
Why?
|
Quality of Life | 2 | 2015 | 1514 | 0.130 |
Why?
|
Peroxiredoxin VI | 1 | 2014 | 18 | 0.130 |
Why?
|
Longitudinal Studies | 1 | 2018 | 1054 | 0.130 |
Why?
|
Leukocytes | 1 | 2014 | 99 | 0.120 |
Why?
|
Health Promotion | 1 | 2018 | 407 | 0.120 |
Why?
|
Association | 1 | 2013 | 5 | 0.120 |
Why?
|
Cooperative Behavior | 1 | 2015 | 235 | 0.120 |
Why?
|
Education, Medical, Continuing | 1 | 2015 | 136 | 0.120 |
Why?
|
Databases, Factual | 2 | 2017 | 621 | 0.120 |
Why?
|
Trauma Centers | 1 | 2015 | 197 | 0.120 |
Why?
|
Anesthesia, General | 1 | 2014 | 86 | 0.120 |
Why?
|
Patient Admission | 2 | 2012 | 99 | 0.120 |
Why?
|
Endothelial Cells | 2 | 2007 | 384 | 0.120 |
Why?
|
Racism | 1 | 2014 | 59 | 0.120 |
Why?
|
Diagnosis, Differential | 5 | 2008 | 1139 | 0.120 |
Why?
|
Intensive Care Units | 1 | 2015 | 344 | 0.120 |
Why?
|
Monocytes | 3 | 2014 | 210 | 0.110 |
Why?
|
Neutrophils | 3 | 2014 | 204 | 0.110 |
Why?
|
Patient Education as Topic | 3 | 2016 | 424 | 0.110 |
Why?
|
Facility Design and Construction | 1 | 2012 | 16 | 0.110 |
Why?
|
Medication Systems, Hospital | 1 | 2012 | 19 | 0.110 |
Why?
|
Patient Care Team | 2 | 2012 | 311 | 0.110 |
Why?
|
Oligonucleotide Array Sequence Analysis | 5 | 2012 | 320 | 0.110 |
Why?
|
Efficiency | 1 | 2012 | 49 | 0.110 |
Why?
|
Chromosomes, Human, Y | 1 | 2012 | 13 | 0.110 |
Why?
|
General Practitioners | 1 | 2012 | 10 | 0.110 |
Why?
|
Child Development Disorders, Pervasive | 1 | 2012 | 26 | 0.110 |
Why?
|
Comprehensive Health Care | 2 | 2021 | 26 | 0.110 |
Why?
|
tau Proteins | 2 | 2002 | 61 | 0.110 |
Why?
|
Embolism | 2 | 2010 | 45 | 0.110 |
Why?
|
Chromosomes, Human, X | 1 | 2011 | 24 | 0.110 |
Why?
|
Perfusion Imaging | 1 | 2011 | 27 | 0.110 |
Why?
|
Genetic Predisposition to Disease | 3 | 2005 | 785 | 0.100 |
Why?
|
Task Performance and Analysis | 1 | 2012 | 150 | 0.100 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2012 | 77 | 0.100 |
Why?
|
Wounds and Injuries | 1 | 2015 | 334 | 0.100 |
Why?
|
Case-Control Studies | 8 | 2012 | 1548 | 0.100 |
Why?
|
Magnetic Resonance Imaging | 2 | 2012 | 2220 | 0.100 |
Why?
|
Health Planning Guidelines | 2 | 2011 | 23 | 0.100 |
Why?
|
Neuroimaging | 1 | 2012 | 122 | 0.100 |
Why?
|
Patient Discharge | 3 | 2020 | 294 | 0.100 |
Why?
|
Medication Adherence | 1 | 2014 | 335 | 0.100 |
Why?
|
Healthcare Disparities | 1 | 2015 | 378 | 0.100 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 201 | 0.100 |
Why?
|
S100 Calcium Binding Protein beta Subunit | 2 | 2008 | 15 | 0.100 |
Why?
|
Therapeutic Equipoise | 1 | 2010 | 3 | 0.100 |
Why?
|
Predictive Value of Tests | 6 | 2013 | 1465 | 0.100 |
Why?
|
Carotid Arteries | 2 | 2008 | 110 | 0.090 |
Why?
|
Intracranial Hemorrhage, Hypertensive | 2 | 2012 | 5 | 0.090 |
Why?
|
Stents | 1 | 2014 | 657 | 0.090 |
Why?
|
Industry | 1 | 2009 | 28 | 0.090 |
Why?
|
Incidence | 6 | 2014 | 1581 | 0.090 |
Why?
|
RNA, Messenger | 1 | 2013 | 1650 | 0.090 |
Why?
|
Conflict of Interest | 1 | 2009 | 48 | 0.090 |
Why?
|
Academic Medical Centers | 1 | 2011 | 281 | 0.090 |
Why?
|
Neurons | 2 | 2006 | 881 | 0.080 |
Why?
|
Urinalysis | 1 | 2008 | 27 | 0.080 |
Why?
|
Drug Therapy, Combination | 3 | 2006 | 648 | 0.080 |
Why?
|
Blood Cells | 1 | 2008 | 27 | 0.080 |
Why?
|
Natriuretic Peptide, Brain | 1 | 2008 | 101 | 0.080 |
Why?
|
Resuscitation | 1 | 2008 | 77 | 0.080 |
Why?
|
Clinical Laboratory Techniques | 1 | 2008 | 60 | 0.080 |
Why?
|
Administration, Intravenous | 2 | 2018 | 89 | 0.080 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2008 | 160 | 0.080 |
Why?
|
Interprofessional Relations | 1 | 2009 | 188 | 0.080 |
Why?
|
Societies | 1 | 2007 | 15 | 0.080 |
Why?
|
Critical Pathways | 1 | 2007 | 33 | 0.080 |
Why?
|
Biomedical Technology | 1 | 2007 | 14 | 0.080 |
Why?
|
Brain Damage, Chronic | 1 | 2006 | 25 | 0.070 |
Why?
|
Cerebral Arteries | 1 | 2006 | 50 | 0.070 |
Why?
|
Sex Factors | 4 | 2017 | 1264 | 0.070 |
Why?
|
Mass Screening | 1 | 2012 | 836 | 0.070 |
Why?
|
Kentucky | 5 | 2005 | 12 | 0.070 |
Why?
|
Brain Infarction | 1 | 2006 | 54 | 0.070 |
Why?
|
Ultrasonography | 1 | 2008 | 452 | 0.070 |
Why?
|
Health Policy | 2 | 2021 | 221 | 0.070 |
Why?
|
Neuroglia | 1 | 2006 | 136 | 0.070 |
Why?
|
Atherosclerosis | 1 | 2008 | 204 | 0.070 |
Why?
|
Social Class | 1 | 2006 | 127 | 0.070 |
Why?
|
Disease Models, Animal | 3 | 2017 | 2548 | 0.070 |
Why?
|
Postoperative Complications | 2 | 2012 | 1615 | 0.070 |
Why?
|
Haplotypes | 1 | 2005 | 174 | 0.070 |
Why?
|
Plasminogen Activators | 1 | 2005 | 19 | 0.070 |
Why?
|
Fee-for-Service Plans | 1 | 2005 | 24 | 0.070 |
Why?
|
Mechanical Thrombolysis | 2 | 2015 | 29 | 0.070 |
Why?
|
Toothache | 1 | 2004 | 7 | 0.070 |
Why?
|
Mental Disorders | 1 | 2010 | 659 | 0.070 |
Why?
|
Computer Simulation | 3 | 2014 | 705 | 0.070 |
Why?
|
Bilirubin | 1 | 2004 | 51 | 0.070 |
Why?
|
Nitrogen Oxides | 1 | 2004 | 7 | 0.070 |
Why?
|
Benzenesulfonates | 1 | 2004 | 30 | 0.060 |
Why?
|
Evidence-Based Medicine | 3 | 2014 | 438 | 0.060 |
Why?
|
Human Growth Hormone | 1 | 2004 | 20 | 0.060 |
Why?
|
Prolactin | 1 | 2004 | 61 | 0.060 |
Why?
|
Injections, Intra-Arterial | 3 | 2014 | 30 | 0.060 |
Why?
|
Heart Diseases | 3 | 2014 | 276 | 0.060 |
Why?
|
Interleukins | 1 | 2004 | 79 | 0.060 |
Why?
|
Hypothermia, Induced | 1 | 2004 | 93 | 0.060 |
Why?
|
Platelet Aggregation Inhibitors | 3 | 2012 | 373 | 0.060 |
Why?
|
International Cooperation | 3 | 2008 | 88 | 0.060 |
Why?
|
Fusobacterium necrophorum | 1 | 2003 | 1 | 0.060 |
Why?
|
Hypercholesterolemia | 1 | 2004 | 86 | 0.060 |
Why?
|
Fusobacterium Infections | 1 | 2003 | 2 | 0.060 |
Why?
|
Pharyngitis | 1 | 2003 | 10 | 0.060 |
Why?
|
Urban Health Services | 1 | 2003 | 24 | 0.060 |
Why?
|
Thrombophlebitis | 1 | 2003 | 47 | 0.060 |
Why?
|
Jugular Veins | 1 | 2003 | 37 | 0.060 |
Why?
|
Education, Continuing | 1 | 2003 | 28 | 0.060 |
Why?
|
Advanced Cardiac Life Support | 1 | 2003 | 22 | 0.060 |
Why?
|
Injections, Intravenous | 3 | 2014 | 215 | 0.060 |
Why?
|
Burns | 1 | 2004 | 83 | 0.060 |
Why?
|
Fibrinolysis | 1 | 2002 | 55 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2017 | 951 | 0.060 |
Why?
|
Syndrome | 3 | 2008 | 255 | 0.060 |
Why?
|
Hydrocortisone | 1 | 2004 | 291 | 0.060 |
Why?
|
Head Injuries, Closed | 1 | 2002 | 9 | 0.050 |
Why?
|
Problem-Based Learning | 1 | 2003 | 72 | 0.050 |
Why?
|
Intracranial Pressure | 1 | 2002 | 58 | 0.050 |
Why?
|
Follow-Up Studies | 3 | 2015 | 3256 | 0.050 |
Why?
|
Inpatients | 2 | 2019 | 208 | 0.050 |
Why?
|
Information Services | 1 | 2002 | 22 | 0.050 |
Why?
|
Anticoagulants | 3 | 2012 | 356 | 0.050 |
Why?
|
Oxygen Inhalation Therapy | 1 | 2002 | 32 | 0.050 |
Why?
|
Secondary Care Centers | 1 | 2021 | 2 | 0.050 |
Why?
|
Decision Trees | 1 | 2002 | 74 | 0.050 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2004 | 212 | 0.050 |
Why?
|
Canada | 2 | 2017 | 266 | 0.050 |
Why?
|
Clinical Decision-Making | 1 | 2021 | 109 | 0.050 |
Why?
|
Age Factors | 3 | 2017 | 1860 | 0.050 |
Why?
|
Comorbidity | 3 | 2017 | 1425 | 0.050 |
Why?
|
Apoptosis | 1 | 2007 | 1639 | 0.050 |
Why?
|
Air Ambulances | 1 | 1999 | 4 | 0.050 |
Why?
|
Edema | 1 | 2000 | 66 | 0.050 |
Why?
|
National Library of Medicine (U.S.) | 1 | 2019 | 1 | 0.050 |
Why?
|
Multivariate Analysis | 3 | 2011 | 1046 | 0.050 |
Why?
|
Cytokines | 1 | 2004 | 866 | 0.050 |
Why?
|
Infusions, Intra-Arterial | 2 | 2010 | 27 | 0.050 |
Why?
|
Apolipoprotein E4 | 3 | 2005 | 31 | 0.050 |
Why?
|
Internship and Residency | 1 | 2005 | 596 | 0.040 |
Why?
|
Probability | 2 | 2012 | 244 | 0.040 |
Why?
|
Internet | 1 | 2002 | 390 | 0.040 |
Why?
|
Animals | 5 | 2017 | 20849 | 0.040 |
Why?
|
Placebo Effect | 1 | 2018 | 20 | 0.040 |
Why?
|
Reproducibility of Results | 3 | 2012 | 2077 | 0.040 |
Why?
|
Medical History Taking | 1 | 1998 | 94 | 0.040 |
Why?
|
Inflammation | 3 | 2014 | 1029 | 0.040 |
Why?
|
Prevalence | 2 | 2013 | 1609 | 0.040 |
Why?
|
Physical Examination | 1 | 1998 | 152 | 0.040 |
Why?
|
Intracranial Aneurysm | 1 | 2019 | 87 | 0.040 |
Why?
|
Administration, Oral | 1 | 2018 | 411 | 0.040 |
Why?
|
Global Health | 2 | 2007 | 135 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2017 | 105 | 0.040 |
Why?
|
Periodontal Abscess | 1 | 1996 | 2 | 0.040 |
Why?
|
Europe | 1 | 2017 | 194 | 0.040 |
Why?
|
Health Resources | 1 | 2017 | 76 | 0.040 |
Why?
|
Pilot Projects | 3 | 2008 | 1341 | 0.040 |
Why?
|
Enterobacteriaceae Infections | 1 | 1996 | 25 | 0.040 |
Why?
|
Cost Savings | 1 | 2017 | 110 | 0.040 |
Why?
|
Candidiasis | 1 | 1996 | 39 | 0.040 |
Why?
|
Australia | 1 | 2017 | 235 | 0.040 |
Why?
|
Bayes Theorem | 1 | 2018 | 303 | 0.040 |
Why?
|
Fatal Outcome | 1 | 1996 | 164 | 0.040 |
Why?
|
North Carolina | 1 | 2016 | 224 | 0.040 |
Why?
|
Health Literacy | 1 | 2016 | 62 | 0.040 |
Why?
|
Health Surveys | 1 | 1998 | 488 | 0.040 |
Why?
|
Cohort Studies | 2 | 2015 | 2356 | 0.040 |
Why?
|
Child, Preschool | 2 | 2014 | 3185 | 0.040 |
Why?
|
Quality Indicators, Health Care | 1 | 2017 | 136 | 0.030 |
Why?
|
Netherlands | 1 | 2015 | 68 | 0.030 |
Why?
|
Embolectomy | 1 | 2015 | 5 | 0.030 |
Why?
|
Reperfusion Injury | 2 | 2008 | 320 | 0.030 |
Why?
|
Focus Groups | 1 | 2016 | 247 | 0.030 |
Why?
|
Medicare | 1 | 2017 | 316 | 0.030 |
Why?
|
Staphylococcal Infections | 1 | 1996 | 156 | 0.030 |
Why?
|
Erythroblasts | 1 | 2014 | 4 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2015 | 85 | 0.030 |
Why?
|
Qualitative Research | 1 | 2016 | 368 | 0.030 |
Why?
|
Megakaryocytes | 1 | 2014 | 18 | 0.030 |
Why?
|
International Classification of Diseases | 1 | 2014 | 85 | 0.030 |
Why?
|
Tomography Scanners, X-Ray Computed | 1 | 2014 | 32 | 0.030 |
Why?
|
Hospitals, University | 2 | 2007 | 169 | 0.030 |
Why?
|
Clinical Trials, Phase III as Topic | 1 | 2014 | 84 | 0.030 |
Why?
|
Disease Progression | 1 | 2018 | 1037 | 0.030 |
Why?
|
Foundations | 1 | 2013 | 17 | 0.030 |
Why?
|
Health Planning | 1 | 2013 | 23 | 0.030 |
Why?
|
Interviews as Topic | 1 | 2015 | 392 | 0.030 |
Why?
|
Gene Regulatory Networks | 1 | 2014 | 94 | 0.030 |
Why?
|
Risk | 2 | 2005 | 563 | 0.030 |
Why?
|
Costs and Cost Analysis | 1 | 2014 | 192 | 0.030 |
Why?
|
Needs Assessment | 1 | 2015 | 185 | 0.030 |
Why?
|
Length of Stay | 1 | 2017 | 780 | 0.030 |
Why?
|
Workflow | 1 | 2014 | 100 | 0.030 |
Why?
|
Cardiovascular Diseases | 2 | 2012 | 938 | 0.030 |
Why?
|
Carotid Artery Diseases | 1 | 2014 | 83 | 0.030 |
Why?
|
Sensitivity and Specificity | 2 | 2008 | 1751 | 0.030 |
Why?
|
Numerical Analysis, Computer-Assisted | 1 | 2013 | 13 | 0.030 |
Why?
|
Multicenter Studies as Topic | 1 | 2013 | 186 | 0.030 |
Why?
|
Alleles | 2 | 2005 | 386 | 0.030 |
Why?
|
Analysis of Variance | 1 | 2015 | 1039 | 0.030 |
Why?
|
Thrombosis | 1 | 2014 | 218 | 0.030 |
Why?
|
Apolipoprotein E2 | 2 | 2002 | 8 | 0.030 |
Why?
|
Blood Coagulation Disorders | 1 | 2012 | 45 | 0.030 |
Why?
|
Sex Distribution | 2 | 2004 | 272 | 0.030 |
Why?
|
Oxidation-Reduction | 1 | 2014 | 566 | 0.030 |
Why?
|
Risk Management | 1 | 2012 | 37 | 0.030 |
Why?
|
Chronic Disease | 1 | 2017 | 1329 | 0.030 |
Why?
|
Bone Plates | 1 | 1992 | 49 | 0.030 |
Why?
|
Age Distribution | 2 | 2004 | 319 | 0.030 |
Why?
|
Regional Blood Flow | 1 | 2012 | 168 | 0.030 |
Why?
|
alpha-Galactosidase | 1 | 2011 | 3 | 0.030 |
Why?
|
Secondary Prevention | 1 | 2013 | 291 | 0.030 |
Why?
|
Risperidone | 1 | 2012 | 48 | 0.030 |
Why?
|
Cervical Vertebrae | 1 | 1992 | 86 | 0.030 |
Why?
|
Molecular Sequence Data | 1 | 2014 | 1442 | 0.030 |
Why?
|
Stochastic Processes | 1 | 2011 | 27 | 0.030 |
Why?
|
Community-Institutional Relations | 1 | 2012 | 59 | 0.030 |
Why?
|
Genotype | 2 | 2005 | 785 | 0.030 |
Why?
|
Spinal Fusion | 1 | 1992 | 90 | 0.030 |
Why?
|
Bone Screws | 1 | 1992 | 90 | 0.030 |
Why?
|
Neurosurgical Procedures | 1 | 2012 | 98 | 0.030 |
Why?
|
Biostatistics | 1 | 2011 | 43 | 0.030 |
Why?
|
Area Under Curve | 1 | 2011 | 238 | 0.020 |
Why?
|
Disabled Persons | 1 | 2012 | 94 | 0.020 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 2 | 2002 | 507 | 0.020 |
Why?
|
Fibrin Tissue Adhesive | 1 | 1990 | 17 | 0.020 |
Why?
|
Dura Mater | 1 | 1990 | 23 | 0.020 |
Why?
|
Hemorrhage | 2 | 2005 | 328 | 0.020 |
Why?
|
RNA | 1 | 2011 | 170 | 0.020 |
Why?
|
Bias | 1 | 2011 | 148 | 0.020 |
Why?
|
Cerebrovascular Circulation | 1 | 2012 | 296 | 0.020 |
Why?
|
Suture Techniques | 1 | 1990 | 75 | 0.020 |
Why?
|
Cholesterol | 1 | 2012 | 331 | 0.020 |
Why?
|
Emergencies | 1 | 2010 | 107 | 0.020 |
Why?
|
Cross-Sectional Studies | 1 | 2017 | 2264 | 0.020 |
Why?
|
Clinical Protocols | 2 | 2002 | 172 | 0.020 |
Why?
|
Transcription Factors | 1 | 2014 | 751 | 0.020 |
Why?
|
Child | 2 | 2012 | 6400 | 0.020 |
Why?
|
Proportional Hazards Models | 1 | 2012 | 791 | 0.020 |
Why?
|
Antipsychotic Agents | 1 | 2012 | 247 | 0.020 |
Why?
|
Protein Processing, Post-Translational | 1 | 2011 | 284 | 0.020 |
Why?
|
Genome-Wide Association Study | 1 | 2010 | 240 | 0.020 |
Why?
|
Up-Regulation | 1 | 2011 | 682 | 0.020 |
Why?
|
Brain Injury, Chronic | 1 | 2008 | 4 | 0.020 |
Why?
|
Guidelines as Topic | 1 | 2009 | 122 | 0.020 |
Why?
|
Prognosis | 2 | 2005 | 2093 | 0.020 |
Why?
|
Caregivers | 1 | 2012 | 365 | 0.020 |
Why?
|
Brain Diseases | 1 | 2008 | 78 | 0.020 |
Why?
|
Models, Statistical | 1 | 2011 | 446 | 0.020 |
Why?
|
Platelet Glycoprotein GPIb-IX Complex | 1 | 2007 | 7 | 0.020 |
Why?
|
Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2007 | 29 | 0.020 |
Why?
|
E-Selectin | 1 | 2007 | 44 | 0.020 |
Why?
|
Cognition Disorders | 1 | 2010 | 342 | 0.020 |
Why?
|
Education | 1 | 2007 | 83 | 0.020 |
Why?
|
Virginia | 1 | 2007 | 45 | 0.020 |
Why?
|
Hospitals, Community | 1 | 2007 | 64 | 0.020 |
Why?
|
Blood Platelets | 1 | 2008 | 284 | 0.020 |
Why?
|
Particle Size | 1 | 2007 | 201 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2007 | 306 | 0.020 |
Why?
|
Necrosis | 1 | 2007 | 239 | 0.020 |
Why?
|
Medical Records | 1 | 2007 | 121 | 0.020 |
Why?
|
Flow Cytometry | 1 | 2007 | 489 | 0.020 |
Why?
|
Introns | 1 | 2005 | 68 | 0.020 |
Why?
|
Linkage Disequilibrium | 1 | 2005 | 91 | 0.020 |
Why?
|
Exons | 1 | 2005 | 122 | 0.020 |
Why?
|
Alberta | 1 | 2005 | 15 | 0.020 |
Why?
|
Infant | 1 | 2012 | 2891 | 0.020 |
Why?
|
Spinal Puncture | 1 | 2004 | 38 | 0.020 |
Why?
|
Hospitals, Urban | 1 | 2004 | 46 | 0.020 |
Why?
|
Sus scrofa | 1 | 2004 | 74 | 0.020 |
Why?
|
Health Services Misuse | 1 | 2004 | 15 | 0.020 |
Why?
|
Stroke Rehabilitation | 1 | 2009 | 334 | 0.020 |
Why?
|
Pregnancy | 1 | 2010 | 2331 | 0.020 |
Why?
|
Body Surface Area | 1 | 2004 | 20 | 0.020 |
Why?
|
Referral and Consultation | 1 | 2007 | 383 | 0.020 |
Why?
|
Immunocompromised Host | 1 | 2004 | 55 | 0.020 |
Why?
|
Polymorphism, Genetic | 1 | 2005 | 301 | 0.020 |
Why?
|
Eligibility Determination | 1 | 2004 | 31 | 0.020 |
Why?
|
Time and Motion Studies | 1 | 2003 | 16 | 0.010 |
Why?
|
Clindamycin | 1 | 2003 | 25 | 0.010 |
Why?
|
Injury Severity Score | 1 | 2004 | 204 | 0.010 |
Why?
|
Metronidazole | 1 | 2003 | 28 | 0.010 |
Why?
|
Midwestern United States | 1 | 2003 | 36 | 0.010 |
Why?
|
Outpatients | 1 | 2004 | 126 | 0.010 |
Why?
|
Mortality | 1 | 2004 | 162 | 0.010 |
Why?
|
Regression Analysis | 1 | 2005 | 737 | 0.010 |
Why?
|
Apolipoprotein E3 | 1 | 2002 | 7 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2012 | 1030 | 0.010 |
Why?
|
Chromatography, Thin Layer | 1 | 2002 | 52 | 0.010 |
Why?
|
Peptides | 1 | 2006 | 455 | 0.010 |
Why?
|
Smoking | 2 | 2002 | 1448 | 0.010 |
Why?
|
Mouth Mucosa | 1 | 2002 | 50 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2005 | 627 | 0.010 |
Why?
|
Informed Consent | 1 | 2003 | 127 | 0.010 |
Why?
|
Immunoblotting | 1 | 2002 | 252 | 0.010 |
Why?
|
Brain Chemistry | 1 | 2002 | 173 | 0.010 |
Why?
|
Health Services Research | 1 | 2003 | 209 | 0.010 |
Why?
|
alpha 1-Antitrypsin | 1 | 2002 | 61 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2002 | 244 | 0.010 |
Why?
|
Teaching | 1 | 2003 | 169 | 0.010 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2004 | 626 | 0.010 |
Why?
|
Demography | 1 | 2002 | 279 | 0.010 |
Why?
|
Educational Status | 1 | 2002 | 273 | 0.010 |
Why?
|
Curriculum | 1 | 2005 | 575 | 0.010 |
Why?
|
Educational Measurement | 1 | 2003 | 254 | 0.010 |
Why?
|
Genetic Testing | 1 | 2002 | 159 | 0.010 |
Why?
|
Program Evaluation | 1 | 2003 | 502 | 0.010 |
Why?
|
Motion Sickness | 1 | 1999 | 6 | 0.010 |
Why?
|
Confusion | 1 | 1999 | 20 | 0.010 |
Why?
|
Autopsy | 1 | 1999 | 56 | 0.010 |
Why?
|
Mutation | 1 | 2005 | 1209 | 0.010 |
Why?
|
Decision Making | 1 | 2003 | 410 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2000 | 567 | 0.010 |
Why?
|
Safety | 1 | 1999 | 145 | 0.010 |
Why?
|
Time Management | 1 | 1999 | 12 | 0.010 |
Why?
|
Analgesics, Opioid | 1 | 2004 | 498 | 0.010 |
Why?
|
Body Mass Index | 1 | 2002 | 866 | 0.010 |
Why?
|
Practice Patterns, Physicians' | 1 | 2002 | 503 | 0.010 |
Why?
|
Echocardiography | 1 | 1999 | 515 | 0.010 |
Why?
|
Anti-Bacterial Agents | 1 | 2003 | 1026 | 0.010 |
Why?
|
Alcohol Drinking | 1 | 2002 | 805 | 0.010 |
Why?
|
Alcoholism | 1 | 2002 | 1109 | 0.010 |
Why?
|
Biomechanical Phenomena | 1 | 1992 | 368 | 0.010 |
Why?
|
Spine | 1 | 1990 | 46 | 0.010 |
Why?
|
Dogs | 1 | 1990 | 490 | 0.010 |
Why?
|
Wound Healing | 1 | 1990 | 260 | 0.010 |
Why?
|